Last refreshed: July 21, 2026 (US ET)
Back to holdings

GILD

Growth

GILEAD SCIENCES INC

Health Care·BiotechnologyYield: Mid (1-3%)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.

Close · 3M

-9.15%

GILD · 3M

-9.15%

Pinch / wheel to zoom · drag to pan · double-tap to reset

Held by 2 AI ETFs

QRFT0.370%

as of Jul 8

AIEQ0.050%

as of Jul 20

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals1
Win rate100% (1/1)
Avg buy return+1.61%
QRFTnow 0.370% of fund2 signals

QRFT · Weight decrease · 2d

weight 0.400% → 0.380% (-0.020 pp)·stock down 3.7% in the 30 days before

Apr 20·entry $135.87·now $133.21

-1.96%
since Apr 20

QRFT · Weight decrease · 2d

weight 0.420% → 0.400% (-0.020 pp)·stock down 3.7% in the 30 days before

Apr 15·entry $139.77·now $133.21

-4.69%
since Apr 15
AIEQnow 0.050% of fund1 signal

AIEQ · New entry · 1d

weight 0 → 0.250% (new)·stock up 4.3% in the 30 days before

May 30·entry $131.10·now $133.21Fresh

+1.61%
since May 30

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Fails the frameworkas of May 2

The AI ETF QRFT is showing a decreasing weight trend in Gilead Sciences, which aligns with our framework's 'Fail' verdict. Both analyses suggest a cautious or negative stance on the company for investment at this time.

  • Circle of CompetenceGilead Sciences operates in the pharmaceutical industry, where established players with diversified portfolios can have reasonably predictable unit economics and cash flows from approved drugs.
  • Economic MoatThe company benefits from strong patent protection on its drugs, regulatory barriers to entry, and established market presence, which collectively form a durable economic moat.
  • ManagementInsufficient information is provided to assess management's candor, capital allocation discipline, or personal alignment with shareholder interests.
  • Financial HealthWhile the reported ROE is high, comprehensive data for a 10-year average ROE, operating margin trends, detailed debt profile, and owner earnings calculation are not available to fully assess financial health.
  • Margin of SafetyWithout projected cash flows or detailed financial statements, it is not possible to estimate intrinsic value and determine if the current price offers a margin of safety.

Gilead Sciences appears to operate within a predictable industry and possesses strong economic moats, making it eligible for initial consideration. However, crucial data points regarding management's capital allocation, comprehensive long-term financial health, and intrinsic value are unavailable. Consequently, the framework cannot confirm the company as a 'wonderful company at a fair price,' resulting in a 'Fail' verdict.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.